Literature DB >> 3501015

Pneumocystis carinii pneumonia following 5-fluorouracil administration.

R Hardy, C Cummings, M Faulkner, I Obianyo.   

Abstract

A 54-year-old man who had been treated with monthly courses of 5-fluorouracil for one year developed Pneumocystis carinii pneumonia. No evidence of significant, permanent, immunologic impairment was evident one year after the patient became infected. An infection associated with 5-fluorouracil treatment is implicated.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3501015      PMCID： PMC2625619     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN： 0027-9684            Impact factor:   1.798


  9 in total

1.  DRUGS EMPLOYED FOR THE SUPPRESSION OF IMMUNOLOGIC RESPONSIVENESS.

Authors:  A C Aisenberg
Journal:  N Engl J Med       Date:  1965-05-27       Impact factor: 91.245

2.  Pneumocystis carinii infection.

Authors:  B A Burke; R A Good
Journal:  Medicine (Baltimore)       Date:  1973-01       Impact factor: 1.889

3.  Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features.

Authors:  P D Walzer; D P Perl; D J Krogstad; P G Rawson; M G Schultz
Journal:  Ann Intern Med       Date:  1974-01       Impact factor: 25.391

4.  Effect of fluoropyrimidines on delayed cutaneous hypersensitivity.

Authors:  S E Blomgren; W H Wolberg; W A Kisken
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

5.  Pneumocystis carinii in lungs of rats treated with cortisone acetate. Ultrastructural observations relating to the life cycle.

Authors:  E G Barton; W G Campbell
Journal:  Am J Pathol       Date:  1969-02       Impact factor: 4.307

Review 6.  NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations.

Authors:  A S Fauci; A M Macher; D L Longo; H C Lane; A H Rook; H Masur; E P Gelmann
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

7.  An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction.

Authors:  H Masur; M A Michelis; J B Greene; I Onorato; R A Stouwe; R S Holzman; G Wormser; L Brettman; M Lange; H W Murray; S Cunningham-Rundles
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

8.  Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.

Authors:  M S Gottlieb; R Schroff; H M Schanker; J D Weisman; P T Fan; R A Wolf; A Saxon
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

9.  Experimental pulmonary Pneumocystis carinii infection in rabbits.

Authors:  W H SHELDON
Journal:  J Exp Med       Date:  1959-07-01       Impact factor: 14.307
  9 in total
  2 in total

1.  An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital.

Authors:  L J Worth; M J Dooley; J F Seymour; L Mileshkin; M A Slavin; K A Thursky
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

2.  Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.

Authors:  Yuichi Ando; Megumi Inada-Inoue; Ayako Mitsuma; Takayuki Yoshino; Atsushi Ohtsu; Naoko Suenaga; Masahiko Sato; Tomoyuki Kakizume; Matthew Robson; Cornelia Quadt; Toshihiko Doi
Journal:  Cancer Sci       Date:  2014-02-13       Impact factor: 6.716
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.